Literature DB >> 26444783

Age and its association with low insulin and high amyloid-β peptides in blood.

Huajie Li1,2, Haihao Zhu1, Max Wallack1, Mkaya Mwamburi3, Samer O Abdul-Hay4, Malcolm A Leissring4, Wei Qiao Qiu1,5.   

Abstract

Age is the major risk factor for developing Alzheimer's disease (AD), and modifying age-related factors may help to delay the onset of the disease. The goal of this study was to investigate the relationship between age and the metabolic factors related to the risk of developing AD. The concentrations of insulin, amylin, and amyloid-β peptide (Aβ) in plasma were measured. We further measured the activity of serum Aβ degradation by using fluorescein- and biotin-labeled Aβ40. Apolipoprotein E4 allele (ApoE4) and cognitive impairment were characterized. Subjects were divided into three age groups: 60-70, 70-80, and ≥80 years old. We found that the older the subjects, the lower the concentration of insulin (p = 0.001) and the higher the concentration of Aβ1-40 (p = 0.004) in plasma. However, age was not associated with the concentration of another pancreatic peptide, amylin, and only marginally with Aβ1-42. These relationships remained in the absence of diabetes, cardiovascular disease, and stroke, and regardless of the presence of ApoE4 and cognitive impairment. Both age and ApoE4 were inversely associated with, while insulin was positively associated with, the activities of Aβ degradation in serum. Our study suggested that low concentration of insulin and high concentration of Aβ40 are aging factors related to the risk of AD.

Entities:  

Keywords:  Alzheimer’s disease; ApoE4; Aβ; Aβ degradation; age; insulin

Mesh:

Substances:

Year:  2016        PMID: 26444783      PMCID: PMC4835689          DOI: 10.3233/JAD-150428

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  39 in total

Review 1.  A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders.

Authors:  R E Tanzi
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 2.  Garbage catastrophe theory of aging: imperfect removal of oxidative damage?

Authors:  A Terman
Journal:  Redox Rep       Date:  2001       Impact factor: 4.412

3.  Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets.

Authors:  A Lukinius; E Wilander; G T Westermark; U Engström; P Westermark
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

4.  Diabetes mellitus and the risk of dementia: The Rotterdam Study.

Authors:  A Ott; R P Stolk; F van Harskamp; H A Pols; A Hofman; M M Breteler
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

Review 5.  Clearing the brain's amyloid cobwebs.

Authors:  D J Selkoe
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

6.  The US economic and social costs of Alzheimer's disease revisited.

Authors:  R L Ernst; J W Hay
Journal:  Am J Public Health       Date:  1994-08       Impact factor: 9.308

7.  Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

Authors:  Malcolm A Leissring; Wesley Farris; Alice Y Chang; Dominic M Walsh; Xining Wu; Xiaoyan Sun; Matthew P Frosch; Dennis J Selkoe
Journal:  Neuron       Date:  2003-12-18       Impact factor: 17.173

8.  Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance.

Authors:  Rita Basu; Elena Breda; Ann L Oberg; Claudia C Powell; Chiara Dalla Man; Ananda Basu; Janet L Vittone; George G Klee; Puneet Arora; Michael D Jensen; Gianna Toffolo; Claudio Cobelli; Robert A Rizza
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

9.  Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy.

Authors:  S M Greenberg; G W Rebeck; J P Vonsattel; T Gomez-Isla; B T Hyman
Journal:  Ann Neurol       Date:  1995-08       Impact factor: 10.422

10.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk.

Authors:  R Mayeux; L S Honig; M-X Tang; J Manly; Y Stern; N Schupf; P D Mehta
Journal:  Neurology       Date:  2003-11-11       Impact factor: 9.910

View more
  4 in total

1.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

2.  Insulin-Degrading Enzyme: Paradoxes and Possibilities.

Authors:  Malcolm A Leissring
Journal:  Cells       Date:  2021-09-16       Impact factor: 6.600

Review 3.  The Role of SGLT2 Inhibitors in Vascular Aging.

Authors:  Le Liu; Yu-Qing Ni; Jun-Kun Zhan; You-Shuo Liu
Journal:  Aging Dis       Date:  2021-08-01       Impact factor: 6.745

4.  Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses.

Authors:  Falah Alhajraf; Deborah Ness; Abdul Hye; Andre Strydom
Journal:  Dev Neurobiol       Date:  2019-09-11       Impact factor: 3.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.